From GlobeNewswire: 2025-02-20 04:08:58

Zealand Pharma announced its financial results for the full year of 2024, highlighting positive clinical advancements in its obesity pipeline. The company reported positive results in trials for petrelintide, dapiglutide, and survodutide, with significant investments secured for R&D. The company’s net operating expenses for 2024 were DKK 1,327.0 million, and it anticipates revenue from existing and new partnerships in 2025. Zealand Pharma also provided updates on its rare disease and chronic inflammation programs, along with sustainability efforts. A conference call will be held to discuss the results further.



Read more at GlobeNewswire: Zealand Pharma Announces Financial Results for